John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: findings from a systematic literature review. Poster presented at the 2019 United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:907.
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. The economic burden of Crohn's disease in Europe: findings from a systematic literature review. Poster presented at the 2019 27th United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:906.
Campbell K, Niare S, Herman Kuiper J. A mathematical model of cartilage regeneration after chondrocyte and stem cell implantation – II: the effects of co-implantation. J Tissue Eng. 2019 Mar 15;10:1-14. doi: 10.1177/2041731419827792
Campbell K, Naire S, Herman Kuiper J. A mathematical model of cartilage regeneration after chondrocyte and stem cell implantation – I: the effects of growth factors. J Tissue Eng. 2019 Mar;10:1-16. doi: 10.1177/2041731419827791
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Camilleri M, Lembo AJ, Lavins BJ, MacDougall JE, Carson RT, Williams VSL, Nelson LM, Shiff SJ, Currie MG, Kurtz CB, Johnston JM. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. United European Gastroenterol J. 2015 Feb 3;3(1):53-62. doi: 10.1177/2050640614555946
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.